CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • FOLD Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • Community Notes

Amicus Therapeutics (FOLD)

Company Profile
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
Amicus Therapeutics logo

Company profile

Ticker
FOLD
Exchange
NASDAQ
Website
www.amicusrx.com
CEO
John Crowley
Employees
Incorporated
Delaware
Location
Pennsylvania
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
Former names
AMICUS THERAPEUTICS INC
SEC CIK
0001178879
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
1.Callidus Biopharma, Inc. • 2.Celenex, Inc. • 3.Scioderm, Inc. • 4.MiaMed, Inc. • 5.Amicus Therapeutics International Holding Limited • 6.Amicus Therapeutics UK Limited • 7.Amicus Therapeutics UK Operations Limited • 8.Amicus Therapeutics SAS • 9.Amicus Therapeutics B.V. • 10.Amicus Therapeutics GmbH ...
IRS number
200422823

FOLD stock data

Analyst ratings and price targets

Last 3 months
BTIG
Maintains
Buy
$16.00
18 Jan 23
Latest filings (excl ownership)
View all
8-K
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
9 Jan 23
8-K
Entry into a Material Definitive Agreement
28 Dec 22
8-K
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
16 Dec 22
8-K
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
16 Nov 22
8-K
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
7 Nov 22
8-K
Entry into a Material Definitive Agreement
7 Nov 22
424B5
Prospectus supplement for primary offering
7 Nov 22
8-K
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
7 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
28 Oct 22
Transcripts
View all
FOLD
Earnings call transcript
2022 Q3
7 Nov 22
FOLD
Earnings call transcript
2022 Q2
5 Aug 22
FOLD
Earnings call transcript
2022 Q1
9 May 22
FOLD
Earnings call transcript
2021 Q4
24 Feb 22
FOLD
Earnings call transcript
2021 Q3
9 Nov 21
FOLD
Earnings call transcript
2021 Q2
6 Aug 21
FOLD
Earnings call transcript
2021 Q1
10 May 21
FOLD
Earnings call transcript
2020 Q4
1 Mar 21
FOLD
Earnings call transcript
2020 Q3
5 Nov 20
FOLD
Earnings call transcript
2020 Q2
10 Aug 20
Latest ownership filings
View all
SC 13G
MORGAN STANLEY
8 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
4
John F Crowley
3 Feb 23
4
Bradley L Campbell
3 Feb 23
SC 13G/A
BlackRock Inc.
31 Jan 23
4
Ellen Rosenberg
25 Jan 23
4
David Michael Clark
19 Jan 23
4
Daphne Quimi
19 Jan 23
4
MARGARET G MCGLYNN
17 Jan 23
4
Ellen Rosenberg
13 Jan 23

Financial summary

Financial statements Chart FOLD financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 281.53 mm 281.53 mm 281.53 mm 281.53 mm 281.53 mm 281.53 mm
Cash burn (monthly) (no burn) 8.96 mm 11.28 mm 21.40 mm 3.88 mm 13.03 mm
Cash used (since last report) n/a 38.99 mm 49.08 mm 93.12 mm 16.86 mm 56.67 mm
Cash remaining n/a 242.54 mm 232.46 mm 188.42 mm 264.67 mm 224.86 mm
Runway (months of cash) n/a 27.1 20.6 8.8 68.3 17.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

FOLD institutional ownership history Ownership history
98.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 217 213 +1.9%
Opened positions 33 27 +22.2%
Closed positions 29 32 -9.4%
Increased positions 71 66 +7.6%
Reduced positions 70 78 -10.3%
13F shares Current Prev Q Change
Total value 3.10 bn 3.62 bn -14.4%
Total shares 275.75 mm 302.17 mm -8.7%
Total puts 311.10 k 218.00 k +42.7%
Total calls 575.80 k 738.00 k -22.0%
Total put/call ratio 0.5 0.3 +82.9%
Largest owners Shares Value Change
Perceptive Advisors 27.37 mm $285.77 mm +1.8%
Avoro Capital Advisors 26.80 mm $279.79 mm 0.0%
Vanguard 25.87 mm $270.10 mm +0.5%
Redmile 21.72 mm $226.75 mm -2.0%
BLK Blackrock 19.90 mm $207.74 mm -1.7%
MS Morgan Stanley 17.18 mm $179.40 mm -6.2%
JHG Janus Henderson 14.78 mm $154.27 mm -11.9%
JPM JPMorgan Chase & Co. 14.34 mm $149.69 mm -9.6%
Palo Alto Investors 9.85 mm $102.81 mm 0.0%
Wellington Management 8.06 mm $84.11 mm -26.9%
Largest transactions Shares Bought/sold Change
STT State Street 0.00 -13.92 mm EXIT
Deutsche Bank AG - Registered Shares 1.56 mm -4.73 mm -75.2%
Wellington Management 8.06 mm -2.97 mm -26.9%
Pictet Asset Management 3.49 mm +2.84 mm +442.0%
JHG Janus Henderson 14.78 mm -2.00 mm -11.9%
Citadel Advisors 1.83 mm -1.90 mm -50.9%
JPM JPMorgan Chase & Co. 14.34 mm -1.53 mm -9.6%
MS Morgan Stanley 17.18 mm -1.13 mm -6.2%
Healthcare Of Ontario Pension Plan Trust Fund 2.63 mm +884.40 k +50.8%
Adage Capital Partners GP, L.L.C. 0.00 -848.16 k EXIT
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

FOLD insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Feb 23 Bradley L Campbell Common Stock Sell Dispose S No Yes 12.9754 20,000 259.51 k 845,129
1 Feb 23 Bradley L Campbell Common Stock Option exercise Acquire M No No 2.45 11,700 28.67 k 865,129
1 Feb 23 Bradley L Campbell Stock Options Common Stock Option exercise Dispose M No No 2.45 11,700 28.67 k 42,225
1 Feb 23 John F Crowley Common Stock Sell Dispose S No Yes 13.1102 147,316 1.93 mm 1,004,669
1 Feb 23 John F Crowley Common Stock Option exercise Acquire M No No 5.13 56,596 290.34 k 1,151,985
1 Feb 23 John F Crowley Common Stock Option exercise Acquire M No No 6.1 83,333 508.33 k 1,095,389
1 Feb 23 John F Crowley Stock Options Common Stock Option exercise Dispose M No No 5.13 56,596 290.34 k 0
1 Feb 23 John F Crowley Stock Options Common Stock Option exercise Dispose M No No 6.1 83,333 508.33 k 0
24 Jan 23 Rosenberg Ellen Common Stock Sell Dispose S No Yes 13.3172 31,839 424.01 k 332,345
18 Jan 23 David Michael Clark Common Stock Sell Dispose S No Yes 13.5 7,382 99.66 k 241,067
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
25 Jan 23
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec.
BTIG Maintains Buy on Amicus Therapeutics, Raises Price Target to $16
18 Jan 23
BTIG analyst Yun Zhong maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $14 to $16.
Looking Into Amicus Therapeutics's Return On Capital Employed
30 Nov 22

Press releases

From Benzinga Pro
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
16 Dec 22
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
15 Nov 22
NEW YORK, NY / ACCESSWIRE / November 15, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ:FOLD). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
14 Nov 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn